Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive

Cocrystal Pharma, Inc.

2025-Q2 EPS reported -$0.43

Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.
Cash and equivalents $4.8M as of June 30, 2025, down from $9.9M at Dec 31, 2024; working capital $4.9M.
Favorable CDI-988 Phase 1 safety/tolerability data for all doses including 1200 mg; Phase 1b norovirus challenge study planned in 2025.
CC-42344 Phase 2a challenge study extended due to low influenza infection rates; compound active against H5N1 avian strain.
R&D expenses $1.1M in Q2 2025 vs $4.3M in Q2 2024; G&A $1.0M vs $1.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.